Navigation Links
Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
Date:10/3/2007

NEW CANAAN, Conn., Oct. 3 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. (Nasdaq: MSHL) will present at the BIO Investor Forum 2007 at the San Francisco Palace Hotel on Thursday, October 11, 2007 at 12:00 pm.

About Marshall Edwards, Inc.

Marshall Edwards, Inc. (Nasdaq: MSHL) is a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from a flavonoid technology platform which has generated a number of novel compounds characterized by broad ranging efficacy against a range of cancer targets with few side effects. The unique combination of efficacy and safety has been explained by their ability to target an enzyme present on the surface of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell. Marshall Edwards, Inc. has licensed rights from Novogen Limited (Nasdaq: NVGN) to bring three oncology drugs -- phenoxodiol, NV-196 and NV-143 -- to market globally. The Company's lead investigational drug, phenoxodiol, is in a Phase III multinational multi-centered clinical trial for patients with recurrent ovarian cancer. More information on the trial can be found at http://www.OVATUREtrial.
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- , - Results From a ... Arthritis in Seven Major Industrialized Countries , , ... say their disease, impacts their ... living with rheumatoid arthritis find shopping for gifts, ... presents most, difficult to do, ...
(Date:12/11/2009)... (Nasdaq: DNDN ) announced today that the ... exercised in full their option to purchase an ... public offering price of $24.75 per share. ... of the offering to an aggregate of 17,250,000 ... receive net proceeds from the offering of approximately ...
(Date:12/11/2009)... a new explanation for differences in the severity of mental ... gene, the more serious the handicap. The genetic defect is ... is the amount of copies of the GDI1 gene that ... American Journal of Human Genetics , and are the result ... VIB, a life sciences research institute in Flanders, Belgium at ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment and dosing ... Center of the first patient in the ACE ( ... fficacy) Phase 2 pivotal trial in patients with relapsed ... a novel, orally available, potent and highly selective small ... kinase-3 (FLT3) inhibitor. The ACE study is designed ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... , ... • chemiluminescence , , ... enzymes exist, their activities having wide-ranging regulatory responses. Many kinases ... as inflammation and cancer, so identifying modulators of kinase and ...
... ... apoptosis • multiplexing • cell based assays ... Apoptosis represents a gene-directed, morphologically and biochemically distinct form of ... of disease states such as cancer, AIDS, neurodegenerative diseases, and ischaemic stroke. ...
... , ... receptor binding assay • LEADseeker • SPA Imaging Beads, ... Chemo-attractant cytokines (chemokines) are low molecular weight, pro-inflammatory cytokines with potent ... are classified into four families (CXC, CC, C, and CXC3) based ...
Other Biology Technology:Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 2The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 3The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 4The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 5The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 6The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 7The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 2The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 3The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 4
(Date:12/14/2009)... study to date of the proteins in a species ... clues to how similar regeneration could be induced in ... at Indiana University-Purdue University Indianapolis and colleagues investigated over ... a type of salamander that has the unique natural ... with the hope that this knowledge will contribute to ...
(Date:12/14/2009)... the United Nations Framework Convention on Climate Change ... hosted the ,Bend the Trend, event on Sunday ... and premiere the screening of the new ,Environmental ... Europe, a joint project of the European Environment ... ESA, is a series of short films showing ...
(Date:12/13/2009)... resolved a question about how a popular class ... biosensors that reveal previously hidden components of chemical ... and hallucinations characterize the illness, people with schizophrenia ... in a particular order, difficulties that interfere with ... well, said Lee Schroeder, a student in the ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2'Environmental Atlas of Europe' unveiled at COP15 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2IWillAgain com Launches Online Community for Athletes Overcoming Accident Illness or Injury 61623 1IWillAgain com Launches Online Community for Athletes Overcoming Accident Illness or Injury 61623 2Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 1Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 2Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 3Knome Launches First Platform Agnostic Human Genome Sequencing and Analysis Service for Researchers 14898 1Knome Launches First Platform Agnostic Human Genome Sequencing and Analysis Service for Researchers 14898 2Knome Launches First Platform Agnostic Human Genome Sequencing and Analysis Service for Researchers 14898 3
... new mission for its Earth science program: to study ... rather than as individual parts. To acknowledge this milestone, ... the accomplishments of 20 years of NASA,s Earth system ... ahead. , Reporters are invited to attend "NASA ...
... cutting-edge medical research, a biomedical engineer at UC Davis ... treatment for infants born with disorders that cause the ... The new approach is based on creating a synthetic ... it could also lead to advances in treating various ...
... . , When someone,s knee hurts with every ... badly damaged that the bones rub together when walking. Medical ... so that patients with such knee problems can walk free ... and blood vessels in the laboratory. The research scientists place ...
Other Biology News:UC Davis bioengineer receives Hartwell Foundation grant to address skull fusion disorder of infants 2Non-wovens as scaffolds for artificial tissue 2
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Inquire...
1M stock solution (238mg/ml)...
...
Biology Products: